Pharmaceuticals
Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
* These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus. * The primary efficacy endpoint was...
2023-10-18 14:00
1440
WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong
* Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain inHong Kong. * HKSTP Park companies will leverage WuXi...
2023-10-18 11:00
1527
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
SUZHOU, China and ROCKVILLE, Md., Oct. 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the registrational Phase III study (HQP1351AG...
2023-10-18 10:11
1474
Bridging the Healthcare Gap in Thailand and Beyond with the Belt and Road Initiative
BANGKOK, Oct. 18, 2023 /PRNewswire/ -- "I have a dream that everyone should have the ability to access medical care equally," says Oraphan Wanacharoen (Ice), BGI Genomics Field Application Scientist. "It's very challenging to achieve such a goal inThailand. With the advanced technology of the com...
2023-10-18 08:21
2254
Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion
SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, term...
2023-10-17 23:17
1924
Ubie's new Generative AI feature for doctors effortlessly summarizes patient findings and streamlines medical record documentation with a 90% User Satisfaction rate.
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie
2023-10-17 23:00
1909
SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedica...
2023-10-17 17:00
3669
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announ...
2023-10-17 08:00
10051
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO）
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with...
2023-10-16 21:50
1751
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
2023-10-16 21:10
1574
TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment
Company champions long-acting HIV therapy with new biologic drug TMB-365/380
combination; after favorable results of Phase1b/2a, company plans to accelerate
Phase 2 clincial study to expedite path to market
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics
2023-10-16 21:00
1452
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapie...
2023-10-16 20:00
1743
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held inBoston, U.S.. These two research...
2023-10-16 18:20
1539
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK),a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, ...
2023-10-16 13:38
1394
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration ...
2023-10-16 09:23
2026
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
2023-10-16 07:48
1335
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
HONG KONG, Oct. 14, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that the "Group" was selected as one of the first echelon of enterprises in The ...
2023-10-14 20:09
2869
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
2687
Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...
2023-10-13 21:47
2707
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
2397
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 294 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 291 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9284
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7761
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
6412
